GlassScriptPhysician profile
Andrew B Covit
NPI 1528058922
$3,140.33
in general payments reported to CMS, 2019-2025
25 companies · $653 in 2025
The $653 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $565 · 2021: $323 · 2022: $371 · 2023: $394 · 2024: $517 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,564.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $665.08 | 2019-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $369.25 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $247.50 | 2021-2025 | |
| Amgen INC. | $228.29 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Vifor Pharma, INC. | $216.59 | 2019-2025 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $203.13 | 2019-2025 | Jynarque |
| Horizon Therapeutics Plc | $200.82 | 2019-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $143.39 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $116.88 | 2019-2025 | Vafseo |
| Mallinckrodt Hospital Products INC. | $106.88 | 2020-2025 | Acthar |
| Ardelyx, INC. | $96.86 | 2024-2025 | Ibsrela |
| Aurinia Pharma U.S., INC. | $95.30 | 2021-2024 | Lupkynis |
| Lilly USA, LLC | $65.84 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $60.84 | 2022-2025 | Benlysta, Jesduvroq |
| Fresenius USA Marketing, INC. | $56.70 | 2019-2025 | Velphoro, Velphoro, Korsuva |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $53.61 | 2020-2022 | |
| Amarin Pharma, INC. | $44.02 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $40.37 | 2024 | |
| Opko Pharmaceuticals, LLC | $27.94 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $23.58 | 2020-2021 | |
| Mallinckrodt Enterprises LLC | $18.59 | 2019 | |
| Apellis Pharmaceuticals, INC. | $16.35 | 2025 | Empaveli |
| Kyowa Kirin, INC. | $16.21 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.50 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Covit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.